FDA Approves Investigational New Drug (IND) Application for Cantrixil (TRX-E-002-1) in Ovarian Cancer

SYDNEY, Sept. 12, 2016 /PRNewswire/ -- Australian oncology-focused biotechnology company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it had received confirmation from the United States Food and Drug Administration (FDA) that the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials